Questions

1057. Deputy Ken O'Flynn asked the Minister for Health whether the Department or the HSE maintains any formal risk register entry relating to governance, financial control, or clinical oversight risks associated with the Treatment Abroad Scheme. [32636/26]

1059. Deputy Ken O'Flynn asked the Minister for Health whether the HSE conducts any ex post review of costs incurred under the Treatment Abroad Scheme to assess variance between estimated and actual expenditure per patient. [32651/26]

1060. Deputy Ken O'Flynn asked the Minister for Health whether any benchmarking is carried out comparing the cost of procedures funded under the Treatment Abroad Scheme across different jurisdictions. [32652/26]

1064. Deputy Ken O'Flynn asked the Minister for Health whether the HSE applies any procedure-specific clinical criteria, risk thresholds, or suitability assessments for gender-related surgical procedures funded under the Treatment Abroad Scheme, beyond the general eligibility criteria outlined. [32656/26]

1120. Deputy Ken O'Flynn asked the Minister for Health whether the staffing model originally developed for a 104-bed facility has been revised to reflect the reduction in capacity to approximately 102 beds and the dementia unit reduction from 19 to 17 beds; and to provide the updated model. [32747/26]

1151. Deputy Ken O'Flynn asked the Minister for Health to outline the clinical specialties and procedures in which third-party insourcing was utilised prior to its reduction; and whether equivalent in-house capacity now exists in each category. [32886/26]

1152. Deputy Ken O'Flynn asked the Minister for Health the number of additional theatre sessions, outpatient clinics, and diagnostic capacity units that have been added within the public system in 2025 and 2026 to replace insourcing activity. [32887/26]

1207. Deputy Ken O'Flynn asked the Minister for Health the way in which clinical risk, patient safety, and service effectiveness are monitored in respect of gender-related healthcare pathways for minors in circumstances where no structured national data collection system is currently in place. [33180/26]

1209. Deputy Ken O'Flynn asked the Minister for Health to identify the specific clinical guidelines currently in active use by clinicians in Ireland for the assessment and referral of minors presenting with gender-related distress, pending completion of the national Model of Care. [33182/26]

1210. Deputy Ken O'Flynn asked the Minister for Health to outline the interim safeguards in place to ensure consistency, evidence-based practice, and protection of minors in the absence of a completed national Model of Care and national audit framework. [33183/26]

1211. Deputy Ken O'Flynn asked the Minister for Health to specify which office, official, or body currently holds ultimate policy and governance responsibility at national level for gender-related assessment and referral pathways for minors; and the statutory or administrative basis on which that responsibility is exercised. [33185/26]

1212. Deputy Ken O'Flynn asked the Minister for Health whether any formal risk assessment has been conducted by her Department or the HSE regarding the operation of gender-related clinical pathways for minors in the absence of a completed national model of care; and if so, to provide the date, scope, and key findings of that assessment. [33186/26]

1214. Deputy Ken O'Flynn asked the Minister for Health to detail what national oversight mechanisms are currently in place within her Department to monitor clinical decision-making, patient outcomes, and safeguarding compliance in respect of minors referred for gender-related healthcare. [33188/26]

1215. Deputy Ken O'Flynn asked the Minister for Health whether any requirement exists at national level for the recording or reporting of clinical outcomes, adverse events, or complications arising from gender-related assessment or referral pathways for minors; and if not, whether such a requirement is under consideration. [33189/26]

1218. Deputy Ken O'Flynn asked the Minister for Health whether any review has been undertaken by her Department into the adequacy of existing safeguarding arrangements in respect of minors accessing gender-related healthcare pathways; and if so, to provide the date and outcome of that review. [33192/26]

1223. Deputy Ken O'Flynn asked the Minister for Health whether she is satisfied that current arrangements meet the State’s obligations in respect of clinical governance, patient safety, and safeguarding, given the absence of national data systems and audit mechanisms. [33202/26]

1224. Deputy Ken O'Flynn asked the Minister for Health whether any adverse event monitoring system exists specifically for gender-related clinical pathways for minors; and if so, to provide details. [33203/26]

1038. Deputy Ken O'Flynn asked the Minister for Health the evidential basis underpinning the decision to cease or substantially reduce the use of third-party insourcing arrangements within the public health system by 30 June 2026; the specific reviews, analyses, or policy papers informing this decision; and if she will provide the dates and authors of such documents. [29806/26]

1039. Deputy Ken O'Flynn asked the Minister for Health whether her Department has conducted a formal impact assessment of the planned cessation or reduction of third-party insourcing on public patient waiting lists; if so, the projected effect on overall waiting list numbers and waiting times; and if she will provide the modelling assumptions used. [29807/26]

1040. Deputy Ken O'Flynn asked the Minister for Health the additional in-house public system capacity, measured in theatre sessions, outpatient clinics, or equivalent activity, that is planned to replace activity currently delivered through third-party insourcing; and the timelines for delivery of this capacity.; and if she will make a statement on the matter. [29808/26]

1041. Deputy Ken O'Flynn asked the Minister for Health her assessment of current waiting list trends, including total numbers and those waiting over 12 months, as reported by the National Treatment Purchase Fund; and how the planned reduction or cessation of insourcing aligns with the objective of reducing waiting lists. [29809/26]

1042. Deputy Ken O'Flynn asked the Minister for Health the specific governance, procurement, or clinical concerns identified in relation to third-party insourcing arrangements which have informed the policy decision to reduce or cease such activity; and the steps taken to address those concerns short of ending insourcing. [29810/26]

1043. Deputy Ken O'Flynn asked the Minister for Health whether a comparative cost-effectiveness analysis has been conducted between third-party insourcing, outsourcing via schemes such as the National Treatment Purchase Fund, and direct in-house provision; and if so, if she will provide a summary of findings. [29811/26]

1044. Deputy Ken O'Flynn asked the Minister for Health the contingency measures in place should waiting lists increase following the reduction or cessation of third-party insourcing; and whether provision exists to reintroduce such arrangements if required to protect patient access. [29812/26]

1066. Deputy Ken O'Flynn asked the Minister for Health the total number of patients currently accessing State-funded pre-exposure prophylaxis (PrEP) under the national programme; and the annual figures for new commencements in each year from 2019 to 2026. [29871/26]